
-
Kenya's economy faces climate change risks: World Bank
-
Trump tariffs hammer global stocks, dollar and oil
-
Mexico president welcomes being left off Trump's new tariffs list
-
Lesotho hardest hit as new US tariffs rattle Africa
-
Stellantis pausing some Canada, Mexico production over Trump auto tariffs
-
Rising odds asteroid that briefly threatened Earth will hit Moon
-
Is the Switch 2 worth the price? Reviews are mixed
-
Countries eye trade talks as Trump tariff blitz roils markets
-
AI could impact 40 percent of jobs worldwide: UN
-
US trade partners eye talks after Trump tariff blitz
-
Dollar, stocks sink as gold hits high on Trump tariffs
-
Trump tariff blitz sparks retaliation threats, economic fears
-
Lessons and liquids: buried alive in Myanmar's earthquake
-
Nintendo Switch 2 sparks excitement despite high price
-
Sri Lanka's crackdown on dogs for India PM's visit sparks protest
-
China vows 'countermeasures' to sweeping new US tariffs
-
Trump jolts allies, foes and markets with tariff blitz
-
How Trump's 'liberation day' tariffs will impact China
-
Europe hits out at Trump tariffs, keeps door open for talks
-
Australia sweats through hottest 12 months on record: official data
-
South African artist champions hyenas in 'eco-queer' quest
-
Taiwan says US tariffs 'highly unreasonable'
-
Trump escalates trade war with sweeping global tariffs
-
China says opposes new US tariffs, vows 'countermeasures'
-
Quake-hit Myanmar's junta chief to head to Bangkok summit
-
New Spielberg, Nolan films teased at CinemaCon
-
Shiny and deadly, unexploded munitions a threat to Gaza children
-
Stocks tank, havens rally as Trump tariffs fan trade war
-
Financial markets tumble after Trump tariff announcement
-
Europe riled, but plans cool-headed response to Trump's tariffs
-
'Shenmue' voted most influential video game ever in UK poll
-
Revealed: Why monkeys are better at yodelling than humans
-
Key details on Trump's market-shaking tariffs
-
US business groups voice dismay at Trump's new tariffs
-
Trump sparks trade war with sweeping global tariffs
-
US stocks end up, but volatility ahead after latest Trump tariffs
-
Boeing chief reports progress to Senate panel after 'serious missteps'
-
Is Musk's political career descending to Earth?
-
On Mexico-US border, Trump's 'Liberation Day' brings fears for future
-
Tesla sales slump as pressure piles on Musk
-
Amazon makes last-minute bid for TikTok: report
-
Tesla first quarter sales sink amid anger over Musk politics
-
World's tiniest pacemaker is smaller than grain of rice
-
Nintendo says Switch 2 console to be launched on June 5
-
Certain foreign firms must 'self-certify' with Trump diversity rules: US embassies
-
Nigerian president sacks board of state oil company
-
Heathrow 'warned about power supply' days before shutdown
-
Epstein accuser Virginia Giuffre 'stable' after car crash
-
Swedish insurer drops $160 mn Tesla stake over labour rights
-
Stock markets mixed as uncertainty rules ahead of Trump tariffs
CMSD | -1.11% | 22.58 | $ | |
JRI | -1.26% | 12.878 | $ | |
RBGPF | -0.41% | 67.72 | $ | |
BCC | -6.56% | 95.79 | $ | |
CMSC | -1.18% | 22.238 | $ | |
NGG | 5.5% | 69.605 | $ | |
SCS | -5.52% | 10.86 | $ | |
GSK | 2.94% | 38.78 | $ | |
RELX | 1.37% | 51.69 | $ | |
BTI | 3.8% | 41.839 | $ | |
AZN | 3.29% | 74.675 | $ | |
BP | -7.78% | 31.37 | $ | |
BCE | 2.15% | 22.3 | $ | |
RYCEF | 0.2% | 9.8 | $ | |
VOD | 2.72% | 9.375 | $ | |
RIO | -1.29% | 59.14 | $ |

Astra warns on falling Covid treatment sales after record year
British Covid vaccine maker AstraZeneca on Thursday warned that coronavirus product sales and profit margins would drop this year as the pandemic recedes and after record-high group revenue in 2021.
AstraZeneca rapidly developed a successful Covid-19 jab during the pandemic that generated full-year sales of almost $4.0 billion (3.5 billion euros) last year, the company said in a results statement.
After initially offering the vaccine at cost, Astra decided in November to begin selling Vaxzevria -- developed alongside University of Oxford -- for profit.
- Covid revenue decline -
Revenue from Covid-19 medicines is set to decline by up to a quarter, AstraZeneca said Thursday.
But total group revenues would increase this year by a "high-teens percentage" thanks in part to sales of antibody treatment Evusheld.
The drug is for high-risk people who show resistance to vaccines against coronavirus.
Astra on Thursday added that its net profit tumbled last year, hit by costs arising from the vast takeover of US biotech firm Alexion.
Profit after tax slumped to $112 million (98 million euros) from $3.2 billion in 2020.
Revenues soared 41 percent to $37.4 billion.
"2021 was an exceptional year for AstraZeneca in terms of revenue, which exceeded $37 billion and was the highest in the company's history," noted chief executive Pascal Soriot.
"This put us well on track to deliver our promise of annual revenue of $40 billion one year ahead of schedule."
He added that AstraZeneca's "rapidly improving financial position" had allowed it to raise its annual dividend payment the first time in a decade.
Soriot said the company last year delivered on its "promise of broad and equitable access" to its Covid-19 vaccine" with 2.5 billion doses released for supply around the world".
At the same time, the group faced vast costs following its $39-billion takeover of Alexion, while large impairment and restructuring charges also weighed.
Astra swung into a pre-tax annual loss of $265 million, after a $3.9-billion profit last time around.
But its share price was up 2.1 percent in London trading Thursday.
"The Covid vaccine has raised Astra's global profile significantly," said Hargreaves Lansdown analyst Keith Bowman.
"For now, and with further innovation and new drug successes ongoing, analyst consensus opinion continues to point to a strong buy" of its shares.
Since taking the helm at AstraZeneca in 2012, Soriot has pushed the company into lucrative treatments such as cancer therapies, and the Alexion takeover gives it more heft in areas such as treating blood disorders.
As for its Covid vaccine, "time spent developing and distributing (the jab)... has been time away from its core business", Bowman added.
"The purchase of Alexion at what is considered a full price is also yet to be fully justified."
Astra's EU's Covid vaccination roll-out was extremely sluggish initially because of a big shortfall in the amount of doses the company had promised the bloc, sparking a row between the parties.
The European Union has since pivoted towards mRNA vaccines, particularly the one produced by US drugs giant Pfizer in partnership with German peer BioNTech, after rare blood-clot problems with AstraZeneca increased public hesitancy about taking it.
D.Avraham--CPN